Biotec: Results from Neuroblastoma Phase II
(Tromsø 13th May 2018) The ongoing vaccine study with Soluble Beta-Glucan (SBG)
from Biotec Pharmacon (Biotec, OSE: BIOTEC) as an oral adjuvant shows very
promising treatment effects in children with relapsed high-risk neuroblastoma.
The immuno-oncology investigators in New York, interpret a promising adjuvant
effect of SBG on cancer vaccine.
The results (outlined below) offer further hope for children with
Neuroblastoma. Additionally, this vaccine/SBG treatment regime has an excellent
safety profile with no observable side-effects, states Chief Scientific
Officer, Rolf Engstad.
The investigator team for the ongoing vaccine study with anti-GD2 vaccine
combined with oral administered SBG has presented new data from 84 patients
with relapsed high-risk neuroblastoma at the Advances in Neuroblastoma Research
2018 conference in San Francisco.
The new data strongly support the initial findings presented in 2014 from the 15
-patient population cohort in the phase I part of the trial, where the two-year
overall survival rate was as high as 92%. In the current phase II part of the
study, having treated additional 84 patients, the 2-year overall survival (OS)
rate was still 90%, with a progression free survival (PFS) rate of 51%.
The long-term survival rate in this patient population, with relapsed high-risk
neuroblastoma, has been less than 20% before introduction of immunotherapeutic
treatment regimes. The study thus gives promise for a significant improvement in
survival rate in this patient group.
When investigating the antibody response to the vaccine, a strong correlation
was observed between high antibody titre to the vaccine, and prognosis for both
improved progression free survival and overall survival. In this high response
subgroup, the overall survival is currently 100% five years into the trial.
Furthermore, a strong increase in the antibody response was observed with the
start of administering SBG as an oral adjuvant in the combined treatment. The
initial justification of using SBG in this combination was to strengthen the
effector functions after an initial immune response was established, but the new
data now indicate that SBG also contributes in inducing an improved immune
response to the vaccine itself. This holds promise for the potential use of SBG
as an oral adjuvant to increase the protective effects of other vaccines.
The role of SBG as an adjuvant to improve the initial immune response to the
vaccine, will be investigated in a follow-up trial.
The results presented by the investigators are very promising. Biotec Pharmacon
will now use the results from the Phase II trial to investigate how to further
develop SBG from both a clinical and strategic point of view, says CEO
Christian Jørgensen.
from Biotec Pharmacon (Biotec, OSE: BIOTEC) as an oral adjuvant shows very
promising treatment effects in children with relapsed high-risk neuroblastoma.
The immuno-oncology investigators in New York, interpret a promising adjuvant
effect of SBG on cancer vaccine.
The results (outlined below) offer further hope for children with
Neuroblastoma. Additionally, this vaccine/SBG treatment regime has an excellent
safety profile with no observable side-effects, states Chief Scientific
Officer, Rolf Engstad.
The investigator team for the ongoing vaccine study with anti-GD2 vaccine
combined with oral administered SBG has presented new data from 84 patients
with relapsed high-risk neuroblastoma at the Advances in Neuroblastoma Research
2018 conference in San Francisco.
The new data strongly support the initial findings presented in 2014 from the 15
-patient population cohort in the phase I part of the trial, where the two-year
overall survival rate was as high as 92%. In the current phase II part of the
study, having treated additional 84 patients, the 2-year overall survival (OS)
rate was still 90%, with a progression free survival (PFS) rate of 51%.
The long-term survival rate in this patient population, with relapsed high-risk
neuroblastoma, has been less than 20% before introduction of immunotherapeutic
treatment regimes. The study thus gives promise for a significant improvement in
survival rate in this patient group.
When investigating the antibody response to the vaccine, a strong correlation
was observed between high antibody titre to the vaccine, and prognosis for both
improved progression free survival and overall survival. In this high response
subgroup, the overall survival is currently 100% five years into the trial.
Furthermore, a strong increase in the antibody response was observed with the
start of administering SBG as an oral adjuvant in the combined treatment. The
initial justification of using SBG in this combination was to strengthen the
effector functions after an initial immune response was established, but the new
data now indicate that SBG also contributes in inducing an improved immune
response to the vaccine itself. This holds promise for the potential use of SBG
as an oral adjuvant to increase the protective effects of other vaccines.
The role of SBG as an adjuvant to improve the initial immune response to the
vaccine, will be investigated in a follow-up trial.
The results presented by the investigators are very promising. Biotec Pharmacon
will now use the results from the Phase II trial to investigate how to further
develop SBG from both a clinical and strategic point of view, says CEO
Christian Jørgensen.
Redigert 19.01.2021 kl 23:29
Du må logge inn for å svare
BioNord
13.05.2018 kl 22:17
3295
E24.no er som vanlig tidlig ute med en kommentar på sine sider
Biotec Pharmacon melder om lovende testresultater
Sammendrag laget av Mail redaktion Eivind Bøe, minE24
Publisert 13 maj 2018, 22.08
NYTT FRA BØRSSELSKAPENE Det Tromsø-baserte bioteknologiselskapet Biotec Pharmacon har fått ferske resultater fra en studie, skriver selskapet i en børsmelding søndag kveld.
Selskapets legemiddel Soluble Beta-Glucan viser «veldig lovende» resultater, skriver selskapet og viser til en vaksinestudie som pågår nå.
Legemiddelet er for behandling av barn med tilbakefallende høyrisikotilfeller av svulstsykdommen nevroblastom.
– Resultatene gir ytterligere håp for barn med nevroblastom. Denne vaksinen eller behandlingsregimet har i tillegg en glimrende sikkerhetsprofil med ingen observerbare bivirkninger, sier forskningssjef Rolf Engstad i meldingen.
Biotec Pharmacon melder om lovende testresultater
Sammendrag laget av Mail redaktion Eivind Bøe, minE24
Publisert 13 maj 2018, 22.08
NYTT FRA BØRSSELSKAPENE Det Tromsø-baserte bioteknologiselskapet Biotec Pharmacon har fått ferske resultater fra en studie, skriver selskapet i en børsmelding søndag kveld.
Selskapets legemiddel Soluble Beta-Glucan viser «veldig lovende» resultater, skriver selskapet og viser til en vaksinestudie som pågår nå.
Legemiddelet er for behandling av barn med tilbakefallende høyrisikotilfeller av svulstsykdommen nevroblastom.
– Resultatene gir ytterligere håp for barn med nevroblastom. Denne vaksinen eller behandlingsregimet har i tillegg en glimrende sikkerhetsprofil med ingen observerbare bivirkninger, sier forskningssjef Rolf Engstad i meldingen.
JosefK
14.05.2018 kl 07:25
3115
Det bar ikke bare hyggelig, det var fantastisk. Neuroblastom drømmen lever og burde åpne for nye lignende konstellasjoner.
dabito
14.05.2018 kl 08:03
3061
Dette avsnittet åpner også for bruk med andre medisiner/behandlinger:
«but the new data now indicate that SBG also contributes in inducing an improved immune
response to the vaccine itself. This holds promise for the potential use of SBG
as an oral adjuvant to increase the protective effects of other vaccines.»
«but the new data now indicate that SBG also contributes in inducing an improved immune
response to the vaccine itself. This holds promise for the potential use of SBG
as an oral adjuvant to increase the protective effects of other vaccines.»
Eller som Lien sier (sa)
Det der nei, liten betalingsvilje, langt fram, usikre greier
Det er ikke noe vi bryr oss om
Det der nei, liten betalingsvilje, langt fram, usikre greier
Det er ikke noe vi bryr oss om
Hallo!!!!
14.05.2018 kl 08:44
2982
Dtt
Hva tenker du resultatene da, visst vi prøver å ha fokus fremover nå?
Hva tenker du resultatene da, visst vi prøver å ha fokus fremover nå?
Redigert 14.05.2018 kl 08:48
Du må logge inn for å svare
bravi
14.05.2018 kl 09:38
2864
jeg tenker det er mange som benytter anledningen å komme seg ut av dette papiret på denne meldingen.
Skal de komme videre med dette trenges penger, da må det bli en en emisjon.
Skal de komme videre med dette trenges penger, da må det bli en en emisjon.
liang
14.05.2018 kl 10:47
2761
Dersom de nå opererer med signifikante positive data i en fase 2 studie så er de vel ved det punktet på utviklingen der BP "overtar/inlisensierer , ikke?